المؤلفون: Werter IM; Department of Medical Oncology/Internal Medicine, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands., Remmelzwaal S; Department of Epidemiology & Data Science, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands., Burchell GL; Medical Library, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands., Konings IR; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.; Lava Therapeutics, Yalelaan 60, 3584 CM Utrecht, The Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

المصدر: Cancers [Cancers (Basel)] 2022 Nov 15; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 15.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: van den Berg K; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Schaap DP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Voogt ELK; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., de Groot JWB; Department of Medical Oncology, Isala Oncology Centre, Zwolle, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Melenhorst J; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., van Westreenen HL; Department of Surgery, Isala, Zwolle, the Netherlands., Aalbers AGJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van 't Veer M; Department of Research and Education, Catharina Hospital, Eindhoven, the Netherlands., Marijnen CAM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands., Vincent J; Department of Medical Oncology, Elkerliek Hospital, Helmond, the Netherlands., Simkens LHJ; Department of Medical Oncology, Maxima Medical Centre, Veldhoven, the Netherlands., Peters NAJB; Department of Medical Oncology, St. Jans Hospital, Weert, the Netherlands., Berbée M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands., Werter IM; Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands., van Lijnschoten IG; Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands., Roef MJ; Department of Nuclear Medicine, Catharina Hospital, Eindhoven, the Netherlands., Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Bloemen JG; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Willems JMWE; Department of Medical Oncology, Anna Hospital, Geldrop, the Netherlands., Creemers GJM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands., Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands. pim.burger@catharinaziekenhuis.nl.

المصدر: BMC cancer [BMC Cancer] 2022 Sep 06; Vol. 22 (1), pp. 957. Date of Electronic Publication: 2022 Sep 06.

نوع المنشور: Clinical Trial Protocol; Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Second Primary*/pathology , Rectal Neoplasms*/pathology, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Camptothecin/analogs & derivatives ; Chemoradiotherapy/methods ; Clinical Trials, Phase II as Topic ; Fluorouracil/therapeutic use ; Humans ; Leucovorin ; Multicenter Studies as Topic ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Organoplatinum Compounds ; Quality of Life ; Treatment Outcome

SCR Protocol: FOLFOXIRI protocol

المؤلفون: Werter IM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. i.werter@vumc.nl., Huijts CM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands., Polee MB; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Los M; Department of Medical Oncology, Saint Antonius Hospital, Nieuwegein, The Netherlands., Haanen JBAG; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Helgason HH; Department of Medical Oncology, Haaglanden Medical Centre, The Hague, The Netherlands., Verheul HM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jj.vandervliet@vumc.nl.

مؤلفون مشاركون: Dutch WIN-O Consortium

المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 May; Vol. 68 (5), pp. 787-798. Date of Electronic Publication: 2019 Feb 11.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell/*drug therapy , Cyclophosphamide/*therapeutic use , Everolimus/*therapeutic use , Immunosuppressive Agents/*therapeutic use , Kidney Neoplasms/*drug therapy , T-Lymphocytes, Regulatory/*immunology, Aged ; Carcinoma, Renal Cell/mortality ; Cell Proliferation ; Female ; Follow-Up Studies ; Humans ; Kidney Neoplasms/mortality ; Male ; Middle Aged ; Survival Analysis ; TOR Serine-Threonine Kinases/metabolism ; Treatment Outcome

المؤلفون: Huijts CM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. c.huijts@vumc.nl., Werter IM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Goedegebuure RS; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis, Rotterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Haanen JB; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Verheul HM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jj.vandervliet@vumc.nl.

مؤلفون مشاركون: Dutch WIN-O Consortium

المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Feb; Vol. 68 (2), pp. 319-329. Date of Electronic Publication: 2018 Nov 09.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Kidney Neoplasms/*drug therapy, Administration, Oral ; Adult ; Aged ; Anemia/chemically induced ; Anorexia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Renal Cell/pathology ; Cohort Studies ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Everolimus/administration & dosage ; Everolimus/adverse effects ; Fatigue/chemically induced ; Female ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis

المؤلفون: Werter IM; Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands., Schneiders FL; Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands., Scotet E; Institut National de la Santé et de la Recherche Médicale; UMR892; Center de Recherche en Cancérologie Nantes-Angers ; Nantes Cedex, France., Verheul HM; Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.

المصدر: Oncoimmunology [Oncoimmunology] 2014 Dec 08; Vol. 3 (9), pp. e955343. Date of Electronic Publication: 2014 Dec 08 (Print Publication: 2014).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE

عنوان ترانسليتريتد: Vaker hersenmetastasen bij colorectaal carcinoom.

المؤلفون: Werter IM; Ziekenhuis Amstelland, Amstelveen., van der Stap D, Bertelsmann FW, van Groeningen CJ

المصدر: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2014; Vol. 158, pp. A7256.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Print Cited Medium: Internet ISSN: 1876-8784 (Electronic) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms/*secondary , Colorectal Neoplasms/*pathology, Aged ; Brain/pathology ; Brain Neoplasms/epidemiology ; Brain Neoplasms/mortality ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/mortality ; Fatal Outcome ; Humans ; Incidence ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male

المؤلفون: Werter IM; Department of Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands., Rustemeijer C

المصدر: The Netherlands journal of medicine [Neth J Med] 2013 Dec; Vol. 71 (10), pp. 508-11.

نوع المنشور: Case Reports; Journal Article; Review

بيانات الدورية: Publisher: Van Zuiden Communications Country of Publication: Netherlands NLM ID: 0356133 Publication Model: Print Cited Medium: Internet ISSN: 1872-9061 (Electronic) Linking ISSN: 03002977 NLM ISO Abbreviation: Neth J Med Subsets: MEDLINE

مواضيع طبية MeSH: Carotid Body Tumor/*diagnosis , Head and Neck Neoplasms/*diagnosis, Age Factors ; Carotid Body Tumor/genetics ; Carotid Body Tumor/therapy ; Diagnosis, Differential ; Genetic Testing ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/therapy ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Treatment Outcome ; Ultrasonography, Doppler